Stanley Cohan, MD
Neurology · Portland, ORNPI 1972788644
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Biogen at 37.5% of the total. Reporting peaked in 2019 at $87,017 and has fallen 98.3% since, to $1,460 in 2025. Among neurology clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $930.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$125K
- EMD Serono, Inc.$65K
- E.r. Squibb & Sons, L.L.C.$35K
- Bristol Myers Squibb$35K
- Sanofi$29K
- Novartis$21K
- plus $24K from 9 others
Across 250 payments — averaging $14,257 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2.1M
- F. Hoffmann-la Roche AG$386K
- Biogen$357K
- AbbVie$338K
- Genentech, Inc.$294K
- Sanofi$30K
- plus $69K from 6 others
What the payments were for
- Consulting fees$152,12446%
- Speaking & faculty fees$152,11346%
- Travel & lodging$16,4845%
- Food & beverage$13,1634%
- Education$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 108 | $125,409 |
| EMD Serono, Inc. | 82 | $64,970 |
| E.r. Squibb & Sons, L.L.C. | 23 | $35,104 |
| Bristol Myers Squibb | 38 | $34,555 |
| Sanofi | 23 | $28,685 |
| Novartis | 56 | $20,851 |
| AbbVie | 5 | $9,244 |
| Genentech USA, Inc. | 4 | $5,745 |
| Merck Kgaa | 1 | $3,440 |
| Genentech, Inc. | 3 | $3,043 |
| AstraZeneca | 6 | $2,262 |
| TG Therapeutics, Inc. | 6 | $412 |
| Amgen | 2 | $211 |
| Teva Pharmaceuticals USA, Inc. | 1 | $59 |
| Sanofi-aventis U.S. LLC | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$334,043 in reported general payments places this provider in the 95th percentile of 228 neurology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 36 | $377,250 |
| VumerityDiroximel Fumarate | 28 | $300,143 |
| Plegridy PenPeginterferon Beta-1a | 20 | $194,244 |
| ZeposiaOzanimod Hydrochloride | 21 | $176,485 |
| MayzentSiponimod | 12 | $107,173 |
| Avonex (4 Pack)Interferon Beta-1a | 13 | $98,645 |
| Teriflunomide | 16 | $22,251 |
| MyrbetriqMirabegron | 17 | $20,041 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $19,148 |
| FingolimodFingolimod Hcl | 45 | $14,086 |
| Dalfampridine ErDalfampridine | 89 | $9,890 |
| Baclofen | 212 | $6,308 |
| Gabapentin | 176 | $5,675 |
| Dimethyl Fumarate | 36 | $5,380 |
| Modafinil | 54 | $4,113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity, Avonex (4 Pack) | $125,409 | $398,78841 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $35,104 | $176,48521 claims |
| NovartisMayzent | $20,851 | $107,17312 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $59 | $50926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 neurology providers in Oregon.
Other neurology in Portland
- Kyle SmootPortland$932K
- Chafic KaramPortland$727K
- Herbert KrobPortland$416K
- Matthew BrodskyPortland$123K
- Delaram SafarpourPortland$77K
- Kiren Kresa-ReahlPortland$71K
- Nizar ChahinPortland$57K
- Jeffrey KayePortland$54K
- Michelle CameronPortland$40K
- Severine KakoPortland$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.